Literature DB >> 26814361

CTRP9 Ameliorates Pulmonary Arterial Hypertension Through Attenuating Inflammation and Improving Endothelial Cell Survival and Function.

Yongxin Li1, Xigang Geng, Haichen Wang, Gesheng Cheng, Suochun Xu.   

Abstract

Endothelial dysfunction and inflammation are believed to be 2 primary instigators of pulmonary arterial hypertension (PH). C1q/TNF-related protein 9 (CTRP9) plays important roles in anti-inflammation and improvement of epithelial function. However, the role of CTRP9 in the progression of PH remains still unclear. In this study, the role and mechanism of CTRP9 in the PH progression were explored. First, serum CTRP9 contents and CTRP9 mRNA expression in the pulmonary artery epithelial cells from patients with PH were detected. Our data on enzyme-linked immunosorbent assay and real-time quantitative Polymerase Chain Reaction showed that CTRP9 mRNA and protein content were markedly downregulated in the patients with PH. Then the pcDNA-CTRP9 expression vector or CTRP9 siRNA was transfected into the primary pulmonary artery epithelial cells from the patients with PH in vitro. CTRP9 overexpression significantly improved endothelial NOS protein expression and reduced the secretion of endothelin-1 (ET-1) and matrix metalloproteinase-2 (MMP-2), whereas knockdown of CTRP9 sharply reduced eNOS protein expression and promoted the secretion of ET-1 and MMP-2 in the cultured human epithelial cells. Moreover, the levels of phosphatidylinositol 3-kinase (PI3K) and pAkt were reduced in the epithelial cells and CTRP9 overexpression activated the PI3K/Akt pathway. CTRP9 could inhibit cell apoptosis and eNOS expression reduction in the cells pretreated with the PI3K/Akt inhibitor LY294002 and resist LY294002-induced ET-1 and MMP-2 secretion. Finally, to verify the role of CTRP9 in the progression of PH in vivo, the pcDNA-CTRP9 expression vector or CTRP9 siRNA was intravenously injected into rats with PH. Pulmonary arterial pressures of the rats were notably reduced by the pcDNA-CTRP9 injection and elevated by the CTRP9 siRNA injection. In conclusion, CTRP9 ameliorated PH by attenuating inflammation and improving endothelial cell survival and function.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26814361     DOI: 10.1097/FJC.0000000000000364

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  14 in total

1.  Overexpression of CTRP9 attenuates the development of atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Chengmin Huang; Peng Zhang; Tingting Li; Jun Li; Tianjiao Liu; Anju Zuo; Jiying Chen; Yuan Guo
Journal:  Mol Cell Biochem       Date:  2018-11-13       Impact factor: 3.396

Review 2.  CTRP family in diseases associated with inflammation and metabolism: molecular mechanisms and clinical implication.

Authors:  Huan Zhang; Zi-Yin Zhang-Sun; Cheng-Xu Xue; Xi-Yang Li; Jun Ren; Yu-Ting Jiang; Tong Liu; Hai-Rong Yao; Juan Zhang; Tian-Tian Gou; Ye Tian; Wang-Rui Lei; Yang Yang
Journal:  Acta Pharmacol Sin       Date:  2022-10-07       Impact factor: 7.169

3.  [Association between serum CTRP9 levels and diabetic retinopathy in patients with type 2 diabetes mellitus].

Authors:  P Zhou; L Liu; W Gao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-03-25

4.  C1q/TNF-related protein-9 ameliorates hypoxia-induced pulmonary hypertension by regulating secretion of endothelin-1 and nitric oxide mediated by AMPK in rats.

Authors:  Qiaoyan Jin; Hui Su; Rui Yang; Yanzhen Tan; Buying Li; Wei Yi; Qianqian Dong; Haifeng Zhang; Wenjuan Xing; Xin Sun
Journal:  Sci Rep       Date:  2021-05-31       Impact factor: 4.379

5.  Identification of Putative Receptors for the Novel Adipokine CTRP3 Using Ligand-Receptor Capture Technology.

Authors:  Ying Li; Tammy Ozment; Gary L Wright; Jonathan M Peterson
Journal:  PLoS One       Date:  2016-10-11       Impact factor: 3.240

6.  C1q/TNF-Related Protein-9 Ameliorates Ox-LDL-Induced Endothelial Dysfunction via PGC-1α/AMPK-Mediated Antioxidant Enzyme Induction.

Authors:  Haijian Sun; Xuexue Zhu; Yuetao Zhou; Weiwei Cai; Liying Qiu
Journal:  Int J Mol Sci       Date:  2017-05-26       Impact factor: 5.923

7.  C1q/TNF-related protein 9 inhibits the cholesterol-induced Vascular smooth muscle cell phenotype switch and cell dysfunction by activating AMP-dependent kinase.

Authors:  Qi Liu; Hui Zhang; Jiale Lin; Ruoxi Zhang; Shuyuan Chen; Wei Liu; Meng Sun; Wenjuan Du; Jingbo Hou; Bo Yu
Journal:  J Cell Mol Med       Date:  2017-05-19       Impact factor: 5.310

8.  Cardiac-derived CTRP9 protects against myocardial ischemia/reperfusion injury via calreticulin-dependent inhibition of apoptosis.

Authors:  Dajun Zhao; Pan Feng; Yang Sun; Zhigang Qin; Zhengbin Zhang; Yanzhen Tan; Erhe Gao; Wayne Bond Lau; Xinliang Ma; Jian Yang; Shiqiang Yu; Xuezeng Xu; Dinghua Yi; Wei Yi
Journal:  Cell Death Dis       Date:  2018-06-20       Impact factor: 8.469

9.  Down-Regulation of miR-34a-5p Potentiates Protective Effect of Adipose-Derived Mesenchymal Stem Cells Against Ischemic Myocardial Infarction by Stimulating the Expression of C1q/Tumor Necrosis Factor-Related Protein-9.

Authors:  Chi-Feng Weng; Ching-Feng Wu; Shao-Hsuan Kao; Jeen-Chen Chen; Hui-Han Lin
Journal:  Front Physiol       Date:  2019-12-17       Impact factor: 4.566

10.  Association of circulating CTRP9 with soluble adhesion molecules and inflammatory markers in patients with type 2 diabetes mellitus and coronary artery disease.

Authors:  Nariman Moradi; Reza Fadaei; Solaleh Emamgholipour; Elham Kazemian; Ghodratollah Panahi; Siamak Vahedi; Lotfolah Saed; Soudabeh Fallah
Journal:  PLoS One       Date:  2018-01-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.